Trial Profile
Natalizumab in Preventing Post-partum Relapses in Multiple Sclerosis
Status:
Recruiting
Phase of Trial:
Phase IV
Latest Information Update: 29 Jul 2019
Price :
$35
*
At a glance
- Drugs Natalizumab (Primary)
- Indications Multiple sclerosis
- Focus Therapeutic Use
- Acronyms NAPPREMS
- 25 Jul 2019 Planned primary completion date changed from 1 Dec 2018 to 1 Dec 2020.
- 31 Aug 2018 Biomarkers information updated
- 11 Feb 2017 New trial record